Targeting Key RNA Methylation Enzymes to Improve the Outcome of Colorectal Cancer Chemotherapy (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2023 Dec 22

PMID 38131226

Authors

Chiyun Shao

Yanjie Han

Yuying Huang

Zhe Zhang

Tao Gong

Yajie Zhang

Xiaokang Tian

Mingzhi Fang

Xuan Han

Min Li

Affiliations

Soon will be listed here.

Abstract

RNA methylation modifications are closely linked to tumor development, migration, invasion and responses to various therapies. Recent studies have shown notable advancements regarding the roles of RNA methylation in tumor immunotherapy, the tumor microenvironment and metabolic reprogramming. However, research on the association between tumor chemoresistance and N6‑methyladenosine (m6A) methyltransferases in specific cancer types is still scarce. Colorectal cancer (CRC) is among the most common gastrointestinal cancers worldwide. Conventional chemotherapy remains the predominant treatment modality for CRC and chemotherapy resistance is the primary cause of treatment failure. The expression levels of m6A methyltransferases, including methyltransferase‑like 3 (METTL3), METTL14 and METTL16, in CRC tissue samples are associated with patients' clinical outcomes and chemotherapy efficacy. Natural pharmaceutical ingredients, such as quercetin, have the potential to act as METTL3 inhibitors to combat chemotherapy resistance in patients with CRC. The present review discussed the various roles of different types of key RNA methylation enzymes in the development of CRC, focusing on the mechanisms associated with chemotherapy resistance. The progress in the development of certain inhibitors is also listed. The potential of using natural remedies to develop antitumor medications that target m6A methylation is also outlined.

Citing Articles

The impact of the ATP-binding cassette (ABC) transporter family on multidrug resistance in head and neck tumors.

Zhang W, Zhu Z, Liu Y Mol Biol Rep. 2025; 52(1):256.

PMID: 39982595 DOI: 10.1007/s11033-025-10321-9.

A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma.

Yu W, Jing Z, Tang J, Chen J Discov Oncol. 2025; 16(1):160.

PMID: 39934434 PMC: 11813854. DOI: 10.1007/s12672-025-01947-z.

METTL1 mediates PKM m7G modification to regulate CD155 expression and promote immune evasion in colorectal cancer.

Wang F, Yang C, Zheng F, Yan Y, Li G, Feng Y J Transl Med. 2024; 22(1):1161.

PMID: 39741310 PMC: 11686999. DOI: 10.1186/s12967-024-05991-1.

METTL protein family: focusing on the occurrence, progression and treatment of cancer.

Zhang H, Sun F, Jiang S, Yang F, Dong X, Liu G Biomark Res. 2024; 12(1):105.

PMID: 39289775 PMC: 11409517. DOI: 10.1186/s40364-024-00652-3.

References

Wang Y, Yang L, Zhang J, Zhou M, Shen L, Deng W . Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. Int J Oncol. 2018; 53(4):1667-1680. DOI: 10.3892/ijo.2018.4514. View

Lu S, Han L, Hu X, Sun T, Xu D, Li Y . N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer. J Hematol Oncol. 2021; 14(1):188. PMC: 8574039. DOI: 10.1186/s13045-021-01204-0. View

Ma S, Zhang J, Yan T, Miao M, Cao Y, Cao Y . Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med. 2023; 12(10):11073-11096. PMC: 10242875. DOI: 10.1002/cam4.5594. View

Lin Z, Wan A, Sun L, Liang H, Niu Y, Deng Y . N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Mol Ther. 2022; 31(2):517-534. PMC: 9931553. DOI: 10.1016/j.ymthe.2022.10.012. View

Liu K, Ouyang Q, Zhan Y, Yin H, Liu B, Tan L . Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment. Mol Ther Nucleic Acids. 2022; 28:464-476. PMC: 9044172. DOI: 10.1016/j.omtn.2022.04.001. View

Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou A . Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the mA reader YTHDF3. Mol Cancer. 2019; 18(1):143. PMC: 6794841. DOI: 10.1186/s12943-019-1079-y. View

Huang W, Li H, Yu Q, Xiao W, Wang D . LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Exp Clin Cancer Res. 2022; 41(1):100. PMC: 8922926. DOI: 10.1186/s13046-022-02319-z. View

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

Hao W, Dian M, Zhou Y, Zhong Q, Pang W, Li Z . Autophagy induction promoted by mA reader YTHDF3 through translation upregulation of FOXO3 mRNA. Nat Commun. 2022; 13(1):5845. PMC: 9532426. DOI: 10.1038/s41467-022-32963-0. View

10.

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

11.

Oskarsson T, Batlle E, Massague J . Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3):306-21. PMC: 3998185. DOI: 10.1016/j.stem.2014.02.002. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Uddin M, Wang Z, Yang C . Dysregulations of Functional RNA Modifications in Cancer, Cancer Stemness and Cancer Therapeutics. Theranostics. 2020; 10(7):3164-3189. PMC: 7053189. DOI: 10.7150/thno.41687. View

14.

Sun L, Wan A, Zhou Z, Chen D, Liang H, Liu C . RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut. 2020; 70(9):1698-1712. PMC: 8355885. DOI: 10.1136/gutjnl-2020-320652. View

15.

Zhao Y, Peng H . The Role of N-Methyladenosine (mA) Methylation Modifications in Hematological Malignancies. Cancers (Basel). 2022; 14(2). PMC: 8774242. DOI: 10.3390/cancers14020332. View

16.

Nishiyama A, Nakanishi M . Navigating the DNA methylation landscape of cancer. Trends Genet. 2021; 37(11):1012-1027. DOI: 10.1016/j.tig.2021.05.002. View

17.

Manna S, Samal P, Basak R, Mitra A, Roy A, Kundu R . Amentoflavone and methyl hesperidin, novel lead molecules targeting epitranscriptomic modulator in acute myeloid leukemia: in silico drug screening and molecular dynamics simulation approach. J Mol Model. 2022; 29(1):9. DOI: 10.1007/s00894-022-05407-1. View

18.

Gilbert W, Bell T, Schaening C . Messenger RNA modifications: Form, distribution, and function. Science. 2016; 352(6292):1408-12. PMC: 5094196. DOI: 10.1126/science.aad8711. View

19.

Chen P, Liu X, Lin X, Gao L, Zhang S, Huang X . Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol Ther Oncolytics. 2021; 20:228-239. PMC: 7873577. DOI: 10.1016/j.omto.2021.01.001. View

20.

Sun K, Du Y, Hou Y, Zhao M, Li J, Du Y . Saikosaponin D exhibits anti-leukemic activity by targeting FTO/mA signaling. Theranostics. 2021; 11(12):5831-5846. PMC: 8058711. DOI: 10.7150/thno.55574. View